πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 91 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 12343380

Expansion of TILs utilizing AKT pathways inhibitors

Iovance Biotherapeutics, Inc. Β· Granted Tue Jul 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 26 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12280140

Processes for production of tumor infiltrating lymphocytes and uses of the same in immunot

Iovance Biotherapeutics, Inc. Β· Granted Tue Apr 22 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12233075

Remnant tumor infiltrating lymphocytes and methods of preparing and using the same

Iovance Biotherapeutics, Inc. Β· Granted Tue Feb 25 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12230378

Systems and methods for coordinating manufacturing of cells for patient-specific immunothe

Iovance Biotherapeutics, Inc. Β· Granted Tue Feb 18 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12226434

Processes for production of tumor infiltrating lymphocytes and uses of same in immunothera

Iovance Biotherapeutics, Inc. Β· Granted Tue Feb 18 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12230379

Systems and methods for coordinating manufacturing of cells for patient-specific immunothe

Iovance Biotherapeutics, Inc. Β· Granted Tue Feb 18 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12194061

Processes for production of tumor infiltrating lymphocytes and uses of same in immunothera

Iovance Biotherapeutics, Inc. Β· Granted Tue Jan 14 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 09 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12188048

Restimulation of cryopreserved tumor infiltrating lymphocytes

Iovance Biotherapeutics, Inc. Β· Granted Tue Jan 07 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 02 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12170134

Systems and methods for coordinating manufacturing of cells for patient-specific immunothe

Iovance Biotherapeutics, Inc. Β· Granted Tue Dec 17 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12159700

Systems and methods for coordinating manufacturing of cells for patient-specific immunothe

Iovance Biotherapeutics, Inc. Β· Granted Tue Dec 03 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 28 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12121541

Processes for production of tumor infiltrating lymphocytes and uses of same in immunothera

Iovance Biotherapeutics, Inc. Β· Granted Tue Oct 22 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 17 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12104172

Processes for generating TIL products enriched for tumor antigen-specific t-cells

Iovance Biotherapeutics, Inc. Β· Granted Tue Oct 01 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12031157

Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses o

Iovance Biotherapeutics, Inc. Β· Granted Tue Jul 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12024718

Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses o

Iovance Biotherapeutics, Inc. Β· Granted Tue Jul 02 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 27 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12023355

Programmed death 1 ligand 1 (PD-L1) binding proteins and methods of use thereof

Iovance Biotherapeutics, Inc. Β· Granted Tue Jul 02 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 27 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11998568

Processes for production of tumor infiltrating lymphocytes and uses of same in immunothera

Iovance Biotherapeutics, Inc. Β· Granted Tue Jun 04 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 30 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11981921

TIL expansion processes using specific cytokine combinations and/or AKTi treatment

Iovance Biotherapeutics, Inc. Β· Granted Tue May 14 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 09 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11975028

Restimulation of cryopreserved tumor infiltrating lymphocytes

Iovance Biotherapeutics, Inc. Β· Granted Tue May 07 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 02 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11969444

Restimulation of cryopreserved tumor infiltrating lymphocytes

Iovance Biotherapeutics, Inc. Β· Granted Tue Apr 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11939596

Processes for production of tumor infiltrating lymphocytes and uses of same in immunothera

Iovance Biotherapeutics, Inc. Β· Granted Tue Mar 26 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 21 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11865140

Restimulation of cryopreserved tumor infiltrating lymphocytes

Iovance Biotherapeutics, Inc. Β· Granted Tue Jan 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11866688

Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses o

Iovance Biotherapeutics, Inc. Β· Granted Tue Jan 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11857573

Restimulation of cryopreserved tumor infiltrating lymphocytes

Iovance Biotherapeutics, Inc. Β· Granted Tue Jan 02 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 28 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11819517

Methods of using tumor infiltrating lymphocytes in double-refractory melanoma

Iovance Biotherapeutics, Inc. Β· Granted Tue Nov 21 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted